T6580

Triflusal

≥98% (HPLC), powder

• Synonim(y): Triflusal, α,α,α-trifluoro-2,4-cresotic acid acetate, 2-(Acetyloxy)-4-(trifluoromethyl)benzoic acid, Drisgen, acetyl-4-trifluoromethylsalicylic acid
• Wzór empiryczny (zapis Hilla): C₁₀H₇F₃O₄
• Numer CAS: 322-79-2
• Masa cząsteczkowa: 248.16
• UNSPSC Code: 12352200
• EC Number: 206-297-5
• NACRES: NA.25
• Assay: ≥98% (HPLC)
• Form: powder
• Quality level: 100

Właściwości

• Quality Level: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to off-white
• solubility: DMSO: >30 mg/mL
• originator: Uriach
• storage temp.: 2-8°C
• SMILES string: FC(F)(F)c1cc(c(cc1)C(=O)O)OC(=O)C
• InChI: 1S/C10H7F3O4/c1-5(14)17-8-4-6(10(11,12)13)2-3-7(8)9(15)16/h2-4H,1H3,(H,15,16)
• InChI key: RMWVZGDJPAKBDE-UHFFFAOYSA-N

Opis

Biochem/physiol Actions

Triflusal is an anti-inflammatory antithrombotic platelet aggregation inhibitor with a 3-fold mechanism of action.

Triflusal is an anti-inflammatory antithrombotic platelet aggregation inhibitor with a 3-fold mechanism of action. It is an irreversible inhibitor of COX-1 inhibiting thromboxane A2, preventing aggregation; it preserves vascular prostacyclin, thus promoting anti-aggregant effect. Triflusal blocks phosphodiesterase leading to an increase in cAMP levels promoting anti-aggregant effect due to inhibition of calcium mobilization.

Features and Benefits

This compound was developed by Uriach. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• pictograms: GHS07
• signalword: Warning
• hcodes: H302,H315,H317,H319,H335
• pcodes: P280 - P301 + P312 + P330 - P302 + P352 - P305 + P351 + P338
• Hazard Classifications: Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
• target_organs: Respiratory system
• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable